Share This
table started by
bioventurist for the BioVenturist Base
There is no user-contributed description yet.
Add More Topics
Save this view to a base, or just for yourself.
about 100 BV: Product topics matching:
Filter this Collection|
|
|
|
|||||
|---|---|---|---|---|---|---|---|
| x name | x image | x Sales | x Stage of development | x Indication or disease | x article | ||
| x Amount | x Year | x Disease | x Phase of development | ||||
| x Donepezil |
|
Donepezil (also misspelled donezepil), marketed under the trade name Aricept by its developer Eisai and partner Pfizer, is a centrally acting reversible acetylcholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's...
|
|||||
| x Sildenafil |
|
1,764,000,000 | 2007 | On the market | Erectile dysfunction | On the market |
Sildenafil citrate, sold as Viagra, Revatio and under various other trade names, is a drug used to treat erectile dysfunction and pulmonary arterial hypertension (PAH). It was developed and is being marketed by the pharmaceutical company Pfizer. It...
|
| 1,657,000,000 | 2006 | ||||||
| 1,645,000,000 | 2005 | ||||||
| x Sertraline |
|
2,110,000,000 | 2006 | On the market | Anxiety | On the market |
Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It was introduced to the market by Pfizer in 1991. Sertraline is primarily used to treat major depression in...
|
| 3,256,000,000 | 2005 | Clinical depression | On the market | ||||
| 531,000,000 | 2007 | ||||||
| x Ziprasidone |
|
589,000,000 | 2005 | On the market | Bipolar disorder | Phase III Clinical Trial |
Ziprasidone (marketed as Geodon, Zeldox by Pfizer) was the fifth atypical antipsychotic to gain FDA approval (February 2001). In the United States, Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia, and...
|
| 854,000,000 | 2007 | Schizophrenia | On the market | ||||
| 758,000,000 | 2006 | Acute Manic Episodes | On the market | ||||
| x Alprazolam |
|
409,000,000 | 2005 | On the market | Anxiety | On the market |
Alprazolam, also known under the trade names Xanax (not to be confused with Zantac), Xanor, Alprax, and Niravam, is a short-acting drug of the benzodiazepine class used to treat moderate to severe anxiety disorders and panic attacks, and is used as...
|
| 316,000,000 | 2006 | ||||||
| 325,000,000 | 2007 | ||||||
| x Linezolid |
|
944,000,000 | 2007 | On the market | Bacterial Infection | On the market |
Linezolid (INN) (pronounced /lɪˈnɛzəlɪd/, li-NE-zə-lid) is a synthetic antibiotic used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics. A member of the oxazolidinone class of...
|
| 618,000,000 | 2005 | Methicillin-resistant Staphylococcus aureus | On the market | ||||
| 782,000,000 | 2006 | ||||||
| x Gabapentin | 431,000,000 | 2007 | On the market | Epilepsy | On the market |
Gabapentin (brand name Neurontin) is a GABA analogue. It was originally developed for the treatment of epilepsy, and currently, gabapentin is widely used to relieve pain, especially neuropathic pain.
Gabapentin was initially synthesized to mimic the...
|
|
| 496,000,000 | 2006 | Postherpetic neuralgia | On the market | ||||
| 639,000,000 | 2005 | ||||||
| x Atorvastatin |
|
12,675,000,000 | 2007 | On the market | LDL Cholesterol Reduction | On the market |
Atorvastatin (INN) (pronounced /əˌtɔrvəˈstætən/) (Lipitor, Pfizer), is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms....
|
| 12,886,000,000 | 2006 | ||||||
| 12,187,000,000 | 2005 | ||||||
| x Celecoxib |
|
2,039,000,000 | 2006 | On the market | Arthritis Pain | On the market |
Celecoxib (INN) (pronounced /sɛlɨˈkɒksɪb/) is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and...
|
| 2,290,000,000 | 2007 | Acute Pain | On the market | ||||
| 1,730,000,000 | 2005 | ||||||
| x Azithromycin |
|
438,000,000 | 2007 | On the market | Malaria | Phase III Clinical Trial |
Azithromycin is an azalide, a subclass of macrolide antibiotics.
Azithromycin is one of the world's best-selling antibiotics, and is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen...
|
| 638,000,000 | 2006 | Bacterial Infection | On the market | ||||
| 2,025,000,000 | 2006 | ||||||
| x Fluconazole |
|
415,000,000 | 2007 | On the market | Fungal Infections | On the market |
Fluconazole (pronounced /fluːˈkɒnəzoʊl/) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections. In a bulk powder form, it appears as a white crystalline powder, and it is very slightly...
|
| 498,000,000 | 2005 | ||||||
| 435,000,000 | 2006 | ||||||
| x Reboxetine |
|
On the market | Neuropathic Pain | Phase II Clinical Trial |
Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD, developed by Pharmacia (now Pfizer). Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox,...
|
||
| Fibromyalgia | Phase III Clinical Trial | ||||||
| x Cetirizine |
|
1,569,000,000 | 2006 | On the market | Allergy | On the market |
Cetirizine hydrochloride (pronounced /sɛˈtɪrɨziːn/), an antihistamine, is a major metabolite of hydroxyzine, and a racemic selective H1 receptor inverse agonist used in the treatment of allergies, hay fever, angioedema, and urticaria. The structural...
|
| 1,541,000,000 | 2007 | ||||||
| 1,362,000,000 | 2005 | ||||||
| 561,000,000 | 2006 | ||||||
| 487,000,000 | 2007 | ||||||
| x Caduet |
|
185,000,000 | 2005 | On the market | LDL Cholesterol Reduction | On the market |
Caduet is a medication approved by the US FDA for the treatment of high cholesterol and high blood pressure. It is a fixed dose combination drug containing amlodipine, a calcium channel blocker (commonly sold as Norvasc), and atorvastatin (Lipitor)....
|
| 586,000,000 | 2007 | Hypertension | On the market | ||||
| 370,000,000 | 2006 | ||||||
| x Tolterodine |
|
988,000,000 | 2005 | On the market | Overactive bladder | On the market |
Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. It is sold under the trade names Detrol and Detrusitol.
Tolterodine acts on M1, M2, M3, M4 and M5 subtypes of muscarinic receptors whereas modern antimuscarinic...
|
| 1,190,000,000 | 2007 | ||||||
| 1,100,000,000 | 2006 | ||||||
| x Doxazosin | 506,000,000 | 2007 | On the market | Hypertension | On the market |
Doxazosin mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura and Carduran, is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.
On February 22, 2005, the US FDA approved a sustained...
|
|
| 538,000,000 | 2006 | Benigh Prostatic Hyperplasia | On the market | ||||
| 586,000,000 | 2005 | ||||||
| x Pregabalin |
|
1,829,000,000 | 2007 | On the market | Epilepsy | Phase III Clinical Trial |
Pregabalin (INN) (pronounced /prɨˈɡæbəlɨn/) is an anticonvulsant drug used for neuropathic pain and as an adjunct therapy for partial seizures with or without secondary generalization in adults. It has also been found effective for generalized...
|
| 291,000,000 | 2005 | Restless legs syndrome | Phase III Clinical Trial | ||||
| 1,156,000,000 | 2006 | Post-Operative Pain | Phase III Clinical Trial | ||||
| Postherpetic neuralgia | On the market | ||||||
| Epilepsy | On the market | ||||||
| more ▼ | |||||||
| x Latanoprost |
|
1,372,000,000 | 2005 | On the market | Ocular hypertension | On the market |
Latanoprost (pronounced la-TA-noe-prost) ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing...
|
| 1,604,000,000 | 2007 | Glaucoma | On the market | ||||
| 1,453,000,000 | 2006 | ||||||
| x Voriconazole |
|
515,000,000 | 2006 | On the market | Fungal Infections | On the market |
Voriconazole (VFEND, Pfizer) is a triazole antifungal medication that is generally used to treat serious, invasive fungal infections. These are generally seen in patients who are immunocompromised, and include invasive candidiasis, invasive...
|
| 632,000,000 | 2007 | ||||||
| 397,000,000 | 2005 | ||||||
| x Irinotecan | 969,000,000 | 2007 | On the market | Colorectal cancer | On the market |
Irinotecan (Camptosar, Pfizer; Campto, Yakult Honsha) is a drug used for the treatment of cancer.
Irinotecan is a topoisomerase 1 inhibitor, which prevents DNA from unwinding. Chemically, it is a semisynthetic analogue of the natural alkaloid...
|
|
| 903,000,000 | 2006 | ||||||
| 910,000,000 | 2005 | ||||||
| x Anidulafungin | On the market | Aspergillosis | Phase III Clinical Trial |
Anidulafungin or Eraxis (Ecalta in Europe) is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it...
|
|||
| x Exemestane | 320,000,000 | 2006 | On the market | Breast cancer | On the market |
Exemestane (trade name Aromasin) is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. An aim in the...
|
|
| 247,000,000 | 2005 | ||||||
| 401,000,000 | 2007 | ||||||
| x Sunitinib | 581,000,000 | 2007 | On the market | Breast cancer | Phase III Clinical Trial |
Sunitinib (marketed as Sutent, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant...
|
|
| 219,000,000 | 2006 | Prostate cancer | Phase II Clinical Trial | ||||
| Colorectal cancer | Phase III Clinical Trial | ||||||
| Genitourinary Cancer | Phase II Clinical Trial | ||||||
| Lung cancer | Phase III Clinical Trial | ||||||
| more ▼ | |||||||
| x Eletriptan |
|
286,000,000 | 2006 | On the market | Migraine | On the market |
Eletriptan (also known as eletriptan hydrobromide) is a second generation triptan drug marketed and manufactured by Pfizer Inc for the treatment of migraine headaches. It is sold in the US under the brand name Relpax.
Relpax was approved by the U.S....
|
| 315,000,000 | 2007 | ||||||
| 233,000,000 | 2005 | ||||||
| x Varenicline |
|
101,000,000 | 2006 | On the market | Smoking cessation | On the market |
Varenicline (trade name Chantix in the USA and Champix in Europe and other countries, marketed by Pfizer, usually in the form of varenicline tartrate) is a prescription medication used to treat smoking addiction. Varenicline is a nicotinic receptor...
|
| 883,000,000 | 2007 | ||||||
| x Maraviroc | On the market | HIV infection | Phase III Clinical Trial |
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a drug used in the treatment of HIV infection.
Maraviroc is an entry inhibitor. Specifically, maraviroc blocks the chemokine receptor CCR5 which HIV uses as a coreceptor to bind and...
|
|||
| Rheumatoid arthritis | Phase II Clinical Trial | ||||||
| x Macugen | On the market | Wet Age-Related Macular Degeneration | On the market | ||||
| x Somavert | On the market | Acromegaly | On the market | ||||
| x Genotropin | 795,000,000 | 2006 | On the market | Growth hormone treatment | On the market | ||
| 808,000,000 | 2005 | ||||||
| 843,000,000 | 2007 | ||||||
| x Donepezil | 401,000,000 | 2007 | On the market | Alzheimer's disease | On the market | ||
| 358,000,000 | 2006 | ||||||
| 346,000,000 | 2005 | ||||||
| x Amlodipine |
|
4,706,000,000 | 2005 | In development | Hypertension | On the market |
Amlodipine (as besylate, mesylate or maleate) is a long-acting calcium channel blocker (dihydropyridine class) used as an anti-hypertensive and in the treatment of angina. Like other calcium channel blockers, amlodipine acts by relaxing the smooth...
|
| 4,866,000,000 | 2006 | ||||||
| 3,001,000,000 | 2007 | ||||||
| x Apixaban |
|
In development | Venous thrombosis | Phase III Clinical Trial |
Apixaban (manufacturer's designation BMS-562247-01) is a compound being investigated as an anticoagulant. It acts by inhibiting coagulation factor Xa. It is presently undergoing phase III trials in the prevention of venous thromboembolism, together...
|
||
| Atrial fibrillation | Phase III Clinical Trial | ||||||
| Venous thrombosis | Phase II Clinical Trial | ||||||
| Acute coronary syndrome | Phase II Clinical Trial | ||||||
| x Axitinib |
|
In development | Renal cell carcinoma | Phase II Clinical Trial |
Axitinib (also known as AG013736) is a small molecule tyrosine kinase inhibitor under development by Pfizer. It inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117). It has...
|
||
| Thyroid cancer | Phase II Clinical Trial | ||||||
| Gastrointestinal cancer | Phase II Clinical Trial | ||||||
| Breast cancer | Phase II Clinical Trial | ||||||
| Lung cancer | Phase II Clinical Trial | ||||||
| more ▼ | |||||||
| x RTP801i-14 | In development | Age-Related Macular Degeneration | Phase II Clinical Trial | ||||
| Diabetic retinopathy | Pre-clinical development | ||||||
| x PF-610,355 | In development | Asthma | Phase II Clinical Trial | ||||
| x UK-432,097 | In development | Chronic Obstructive Pulmonary Disease | Phase II Clinical Trial | ||||
| x PF-3,893,787 | In development | Asthma | Phase I Clinical Trial | ||||
| x PF-4,191,834 | In development | Asthma | Phase I Clinical Trial | ||||
| x PF-3,526,299 | In development | Asthma | Phase I Clinical Trial | ||||
| x PF-489,791 | In development | Chronic Obstructive Pulmonary Disease | Phase I Clinical Trial | ||||
| Pulmonary hypertension | Phase I Clinical Trial | ||||||
| x CP-945,598 | In development | Obesity | Phase III Clinical Trial | ||||
| x CP-866,087 | In development | Obesity | Phase II Clinical Trial | ||||
| x PF-734,200 | In development | Diabetes mellitus type 2 | Phase II Clinical Trial | ||||
| x PD-348,292 | In development | Thrombosis | Phase II Clinical Trial | ||||
| x CP-533,536 | In development | Bone healing | Phase II Clinical Trial | ||||
| x CE-326,597 | In development | Obesity | Phase II Clinical Trial | ||||
| x CP-800,569 | In development | Atherosclerosis | Phase I Clinical Trial | ||||
| x PF-3,185,043 | In development | Atherosclerosis | Phase I Clinical Trial | ||||
| x PF-2,575,799 | In development | Obesity | Phase I Clinical Trial | ||||
| x PF-4,603,629 | In development | Diabetes mellitus | Phase I Clinical Trial | ||||
| x PF-4,325,667 | In development | Obesity | Phase I Clinical Trial | ||||
| x PF-885,706 | In development | Gastroesophageal reflux disease | Phase II Clinical Trial | ||||
| x PF-4,548,043 | In development | Gastroesophageal reflux disease | Phase I Clinical Trial | ||||
| x PF-2,391,677 | In development | Gastroesophageal reflux disease | Phase I Clinical Trial | ||||
| x PF-4,136,309 | In development | Liver disease | Phase I Clinical Trial | ||||
| Pain | Phase I Clinical Trial | ||||||
| x UK-369,003 | In development | Lower urinary tract symptoms | Phase II Clinical Trial | ||||
| x PF-446,687 | In development | Sexual Health | Phase I Clinical Trial | ||||
| x PF-3,274,167 | In development | Urinary incontinence | Phase I Clinical Trial | ||||
| x PD-299,685 | In development | Genitourinary Disease | Phase I Clinical Trial | ||||
| x UK-453,061 |
|
In development | HIV infection | Phase II Clinical Trial | |||
